📊 CLDX Key Takeaways
Is Celldex Therapeutics, Inc. (CLDX) a Good Investment?
Celldex faces critical near-term survival risk with only $35.7M cash against quarterly burn of ~$65.6M, providing less than one quarter of runway. Revenue has collapsed 78% YoY to just $15K, while the company operates at a massive -$84.4M operating loss with negative free cash flow of -$67.2M, indicating unsustainable business fundamentals absent immediate turnaround or capital infusion.
Celldex’s fundamentals are dominated by a clinical-stage biotech profile with minimal revenue, extremely negative margins, and very large operating and free cash flow losses. While the balance sheet shows low leverage, the combination of a 78% revenue decline and roughly $211M of operating cash burn against only $28.87M of cash creates a weak near-term financial picture and raises sustainability concerns.
Celldex Therapeutics, Inc. Key Strengths (CLDX)
- Strong balance sheet with $456.2M stockholders equity and $511.3M total assets
- Zero debt (0.00x debt-to-equity) with no interest coverage concerns
- Excellent liquidity position with 8.92x current ratio providing short-term flexibility
- Debt-free capital structure with 0.00x debt-to-equity
- Very strong reported liquidity ratios at 10.49x current and quick ratio
- Large equity base of $527.16M relative to liabilities of $55.82M
CLDX Stock Risks: Celldex Therapeutics, Inc. Investment Risks
- Critical cash runway of <1 quarter at current burn rate ($35.7M cash vs -$65.6M operating cash flow)
- Catastrophic revenue decline of 78% YoY with only $15K revenue base suggesting major commercial or operational failure
- Unsustainable cash burn with -$67.2M free cash flow and no path to profitability evident in near term
- Zero insider activity in last 90 days suggests management confidence concerns or freeze pending major announcements
- Company appears to be in advanced distress requiring immediate capital raise, restructuring, or acquisition
- Revenue base is very small and fell 78.0% year over year
- Profitability is extremely weak with operating margin of -18599.8% and net margin of -16748.0%
- Cash burn is severe, with -$210.94M operating cash flow and -$213.66M free cash flow
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Any capital raise announcements or debt financing activity
- Revenue trajectory and new product commercialization progress
- Cash runway versus quarterly operating cash burn
- Revenue durability and any improvement in operating loss trend
Celldex Therapeutics, Inc. (CLDX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.92x current ratio provides a solid financial cushion.
CLDX Profit Margin, ROE & Profitability Analysis
CLDX vs Healthcare Sector: How Celldex Therapeutics, Inc. Compares
How Celldex Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Celldex Therapeutics, Inc. Stock Overvalued? CLDX Valuation Analysis 2026
Based on fundamental analysis, Celldex Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Celldex Therapeutics, Inc. Balance Sheet: CLDX Debt, Cash & Liquidity
CLDX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Celldex Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 5% decline. The most recent EPS of $-2.92 indicates the company is currently unprofitable.
CLDX Revenue Growth, EPS Growth & YoY Performance
CLDX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.0K | -$53.8M | $-0.81 |
| Q3 2025 | $1.4M | -$32.8M | $-0.64 |
| Q2 2025 | $730.0K | -$32.8M | $-0.54 |
| Q1 2025 | $156.0K | N/A | $-0.56 |
| Q3 2024 | $1.5M | N/A | $-0.64 |
| Q2 2024 | $268.0K | N/A | $-0.54 |
| Q1 2024 | $156.0K | N/A | $-0.56 |
| Q3 2023 | $407.0K | N/A | $-0.57 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Celldex Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CLDX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Celldex Therapeutics, Inc. (CIK: 0000744218)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CLDX
What is the AI rating for CLDX?
Celldex Therapeutics, Inc. (CLDX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CLDX's key strengths?
Claude: Strong balance sheet with $456.2M stockholders equity and $511.3M total assets. Zero debt (0.00x debt-to-equity) with no interest coverage concerns. ChatGPT: Debt-free capital structure with 0.00x debt-to-equity. Very strong reported liquidity ratios at 10.49x current and quick ratio.
What are the risks of investing in CLDX?
Claude: Critical cash runway of <1 quarter at current burn rate ($35.7M cash vs -$65.6M operating cash flow). Catastrophic revenue decline of 78% YoY with only $15K revenue base suggesting major commercial or operational failure. ChatGPT: Revenue base is very small and fell 78.0% year over year. Profitability is extremely weak with operating margin of -18599.8% and net margin of -16748.0%.
What is CLDX's revenue and growth?
Celldex Therapeutics, Inc. reported revenue of $15.0K.
Does CLDX pay dividends?
Celldex Therapeutics, Inc. does not currently pay dividends.
Where can I find CLDX SEC filings?
Official SEC filings for Celldex Therapeutics, Inc. (CIK: 0000744218) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CLDX's EPS?
Celldex Therapeutics, Inc. has a diluted EPS of $-1.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CLDX's fundamental grade?
Based on our AI fundamental analysis in June 2026, Celldex Therapeutics, Inc. has a D grade with 87% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CLDX stock overvalued or undervalued?
Valuation metrics for CLDX: ROE of -17.2% (sector avg: 15%), net margin of -524,566.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CLDX's AI grade for 2026?
Our dual AI analysis gives Celldex Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CLDX's free cash flow?
Celldex Therapeutics, Inc.'s operating cash flow is $-65.6M, with capital expenditures of $1.6M. FCF margin is -448,180.0%.
How does CLDX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -524,566.7% (avg: 12%), ROE -17.2% (avg: 15%), current ratio 8.92 (avg: 2).